01/01/2009 - Role of transporters in drug ADME

Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity

Heredi-Szabo K, Glavinas H, Kis E, Mehn D, Bathori G, Veres Z, Kobori L, von Richter O, Jemnitz K, Krajcsi P. DRUG METAB DISPOS. 2009 37(4):794-801. doi: 10.1124/dmd.108.023895. PubMed PMID: 19118132.

Abstract

Multidrug resistance protein 2 (MRP2) is a multispecific organic anion transporter expressed at important pharmacological barriers, including the canalicular membrane of hepatocytes. At this location it is involved in the elimination of both endogenous and exogenous waste products, mostly as conjugates, to the bile. Estradiol-17beta-d-glucuronide (E(2)17betaG), a widely studied endogenous substrate of MRP2, was shown earlier to recognize two binding sites of the transporter in vesicular transport assays. MRP2 modulators (substrates and nonsubstrates) potentiate the transport of E(2)17betaG by MRP2. We correlated data obtained from studies of different complexities and investigated the species-specific differences between rat and human MRP2-mediated transport. We used vesicular transport assays, sandwich-cultured primary hepatocytes, and in vivo biliary efflux in rats. Our results demonstrate that the rat Mrp2 transporter, unlike the human MRP2, transports E(2)17betaG according to Michaelis-Menten type kinetics. Nevertheless, in the presence of modulator drugs E(2)17betaG transport mediated by the rat transporter also shows cooperative kinetics as potentiation of E(2)17betaG transport was observed in the vesicular transport assay. We also demonstrated that the potentiation exists both in rat and in human hepatocytes and in vivo in rats.

open_in_new Read the Source

Next: Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2

Previous: Leflunomide and A771726, its metabolite are high affinity substrates of BCRP - implications for drug resistance